Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
10/30/15
Vaccinex provided corporate sponsorship and presented information on its current SIGNAL clinical trial (phase 2 trial of VX15 antibody in Huntington’s disease) at the 2015 Huntington Study Group Annual Meeting in Tampa, Fl
10/28/15
Vaccinex Announces Publication of Vaccinex-Authored Review of SEMA4D in Oncoimmunology
10/27/15
Vaccinex to present its ActivMAb® Antibody Discovery Technology at the 2015 PEGS Europe Summit
10/20/15
Vaccinex announces publication of results from a Phase I trial of anti-Semaphorin 4D antibody, VX15/2503, in patients with advanced solid tumors
10/06/15
Vaccinex announces publication on the generation, characterization and preclinical evaluation of its lead clinical-stage antibody VX15/2503
06/24/15
Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)
05/11/15
Vaccinex Announces Publication of VX15/2503 Non-clinical Toxicology Studies
03/31/15
Vaccinex Provides an Update on Its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients
03/26/15
Vaccinex Publishes Information about its Novel Anti-CXCL13 Antibody for Autoimmune Disease
03/26/15
Vaccinex to Present Preclinical Anti-Semaphorin 4D Data at AACR
03/19/15
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
02/16/15
Vaccinex announces the publication of data demonstrating preclinical efficacy in an animal model of Huntington Disease
01/26/15
Vaccinex announces groundbreaking preclinical data demonstrating an immunomodulatory role for anti-SEMA4D antibody blockade in colon and breast cancer